title: In Reply to Kishan et al.
authors.affiliation: Division of Radiation Oncology, Department of Oncology, Western University and London Regional Cancer Program, London, ON, Canada.
authors.forename: Glenn
authors.initials: G
authors.lastname: Bauman
authors.affiliation: Division of Radiation Oncology, Department of Oncology, Western University and London Regional Cancer Program, London, ON, Canada.
authors.forename: George
authors.initials: G
authors.lastname: Rodrigues
authors.affiliation: Division of Radiation Oncology, Department of Oncology, Western University and London Regional Cancer Program, London, ON, Canada.
authors.forename: Jeff
authors.initials: J
authors.lastname: Chen
authors.affiliation: Department of Radiation Medicine, University of Toronto and Odette Cancer Center, Toronto, ON, Canada.
authors.forename: Andrew
authors.initials: A
authors.lastname: Loblaw
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery*
chemical_list: D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone